Molecular target
Nicotinic Acetylcholine Receptor (α4β2)
Pentameric ligand-gated ion channel mediating nicotinic neurotransmission. The α4β2 subtype is the primary target of varenicline (partial agonist) for smoking cessation. Lobelia's lobeline is a structurally distinct nicotinic partial agonist with parallel pharmacology.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on Nicotinic Acetylcholine Receptor (α4β2)
These medications have Nicotinic Acetylcholine Receptor (α4β2) among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on Nicotinic Acetylcholine Receptor (α4β2)
Each plant below contains a named compound documented to act on Nicotinic Acetylcholine Receptor (α4β2). The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- NicotinePyridine alkaloid
Nicotine is a potent agonist at nicotinic acetylcholine receptors (nAChR, notably α4β2 subtype), driving dopamine and norepinephrine release via DAT and NET modulation; also reported to inhibit MAO-A and MAO-B in vitro. Responsible for stimulant and addictive properties of tobacco products.
- NornicotinePyridine alkaloid
Demethylated metabolite of nicotine; also active at nAChR. Serves as the precursor to the carcinogen N'-nitrosonornicotine (NNN) during curing and processing, per Siminszky et al. (2005).
- Anabasine / AnatabinePyridine alkaloids
Minor tobacco alkaloids; activity at nAChR documented in molecular genetics literature (Dewey et al., 2013).
- NicotinePyridine alkaloid
Primary psychoactive alkaloid — α4β2 nicotinic acetylcholine receptor agonist with high affinity. The pharmacology that drives both the addictive potential of smoking and the therapeutic application in nicotine replacement therapy.
- Nornicotine, anabasinePyridine alkaloid
Auxiliary nicotinic alkaloids. Anabasine is more concentrated in N. rustica (sacred tobacco) than N. tabacum.
- ConiinePiperidine alkaloid
Bowman et al. (1963) describe coniine as a nicotinic acetylcholine receptor (nAChR) agonist/antagonist with depolarising neuromuscular blocking properties, producing ascending flaccid paralysis. Sodium channel activity has also been reported in mechanistic studies.
- γ-ConiceinePiperidine alkaloid
Considered the predominant alkaloid in early growth stages; shares nicotinic receptor activity with coniine and is reported to be more acutely toxic in livestock studies (López et al., 1999).
- LobelinePiperidine alkaloid
Structurally distinct from nicotine and varenicline but with nicotinic-partial-agonist activity. Mechanism plausibility for smoking cessation is real; clinical evidence has been mixed despite rationale.
- LobelaninePiperidine alkaloid
Secondary alkaloid; contributes to nicotinic activity profile.
- MethylcytisineQuinolizidine alkaloid
Nicotinic acetylcholine receptor agonist; case report data associate methylcytisine with nicotinic toxidrome (tachycardia, diaphoresis, muscle fasciculations) following high-dose ingestion (Rao et al. 2002).
- Ginsenosides (Rb1, Rg1, Re)Triterpenoid saponins
Preclinical studies indicate interactions with nicotinic acetylcholine receptors and NMDA glutamate receptors; HPA-axis modulation has been proposed as a mechanism underlying reported effects on fatigue and cognition. Evidence is largely preclinical.
- Quinolizidine alkaloids (cytisine, anagyrine)Alkaloid
Cytisine is a well-characterised partial agonist at nicotinic acetylcholine receptors (α4β2 subtype). This mechanistic activity is established for the isolated compound class; its relevance to whole-plant Baptisia preparations at typical doses is not established by available citations.